

2022

2022.8

2022

6

- 2010 6
- 2011 6
- 2012 2;
- 2012 9 IND 2013 9
- 2016 9 2 HMS5552 2
- 2018 9
- 2020 8 HMS5552
- 2020 9 3
- 2021 4 HMS5552
- 2021 5

/ÇÜÉÄL&v













,



Copyright © Hua Medicine 2022






Rank	Country or territory	Total diabetes-related health expenditure in [illegible] adults (20–79 years)
[illegible]	[illegible]	379.5
1	United States of America	165.3
2	China	42.9
3	Brazil	41.3
4	Germany	35.6
5	Japan	23.4
6	United Kingdom	22.7
7	France	19.9
8	Mexico	15.5
9	Spain	14.7
10	Italy	


Copyright © Hua Medicine 2022

FIC



II


III SEED DAWN



DREAM SEED 2

Copyright © Hua Medicine 2022





1		
2		10
3		-
4		2
5		-
6		-

Copyright © Hua Medicine 2022

- - 5 13 , GKA
- KOL
- SEED DAWN 80 5 28
- 6 5 Dream 5









MODY-2

- GCK 2 (MODY-2)
  -
  -
- β
-

GK-MODY





Source: E Chow, E Ferrannini, J Chan, 2022 ADA 261-OR Diabetes 2022;71(Supplement_1):261-OR

Copyright © Hua Medicine 2022

- SEED DAWN 43%-45%
- IGI&DI SEED DAWN HbA1c<7%
- IGI DI



Source: LG Feng, L Chen, WY Yang, 2022 ADA 117-LB
Diabetes 2022;71(Supplement_1):117-LB

Copyright © Hua Medicine 2022



Week 52

Source: JH Ma, et al 2022 ADA 115-LB
Diabetes 2022;71(Supplement_1):115-LB

Matthew C Riddle, et al. Diabetes Care. 2021 Aug 30;44(10):2438-2444.

Copyright © Hua Medicine 2022

2

β

Copyright © Hua Medicine 2022


DREAM

SEED HOMA2-β HOMA2-IR DI IGI

ΔC30/ΔG30 44%

HOMA2-β HOMA2-iIR DI

ΔC30/ΔG30




Before dorzagliatin treatment

After dorzagliatin treatment


Copyright © Hua Medicine 2022


H
H M

- 2034
- 2037-39
- GKA




Copyright © Hua Medicine 2022



1

2

Copyright © Hua Medicine 2022







&





Arch Ventures

juno THERAPEUTICS

DENALI THERAPEUTICS

Dorzagliatin

III

52

-

T2D 52


H
H M

_____	2022	2021		1.046	1.653
_____	2022	2021		72.3	98.0
			15.6		SEED/HMM

Copyright © Hua Medicine 2022

	2022	2021
	68.5	63.5

6.9 2022

NDA 2021

1.2

0.4 0.5 2022

2021

Copyright © Hua Medicine 2022




HUA
HM